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Prediction of urinary protein markers in lupus nephritis.
Background. Lupus nephritis is divided into six classes and
scored according to activity and chronicity indices based on
histologic findings. Treatment differs based on the pathologic
findings. Renal biopsy is currently the only way to accurately
predict class and activity and chronicity indices. We propose to
use patterns of abundance of urine proteins to identify class and
disease indices.
Methods. Urine was collected from 20 consecutive patients
immediately prior to biopsy for evaluation of lupus nephritis.
The International Society of Nephrology/Renal Pathology So-
ciety (ISN/RPS) class of lupus nephritis, activity, and chronic-
ity indices were determined by a renal pathologist. Proteins
were separated by two-dimensional gel electrophoresis. Arti-
ficial neural networks were trained on normalized spot abun-
dance values.
Results. Biopsy specimens were classified in the database ac-
cording to ISN/RPS class, activity, and chronicity. Nine samples
had characteristics of more than one class present. Receiver
operating characteristic (ROC) curves of the trained networks
demonstrated areas under the curve ranging from 0.85 to 0.95.
The sensitivity and specificity for the ISN/RPS classes were
class II 100%, 100%; III 86%, 100%; IV 100%, 92%; and V
92%, 50%. Activity and chronicity indices had r values of 0.77
and 0.87, respectively. A list of spots was obtained that provided
diagnostic sensitivity to the analysis.
Conclusion. We have identified a list of protein spots that
can be used to develop a clinical assay to predict ISN/RPS class
and chronicity for patients with lupus nephritis. An assay based
on antibodies against these spots could eliminate the need for
renal biopsy, allow frequent evaluation of disease status, and
begin specific therapy for patients with lupus nephritis.
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Patients with systemic lupus erythematosus (SLE) fre-
quently develop renal disease that may lead to end-
stage renal disease (ESRD). In 2002, 1100 patients
developed ESRD secondary to SLE, a 12% increase
from the previous year [1]. The renal disease of SLE has
been divided into six classes by the International Soci-
ety of Nephrology/Renal Pathology Society (ISN/RPS):
class I, mesangial immune deposits; class II, mesan-
gial immune deposits with mesangial hypercellularity;
class III, proliferative glomerulonephritis involving
<50% of glomeruli; class IV, proliferative glomeru-
lonephritis involving ≥50% of glomeruli; class V, mem-
branous nephritis; and class VI, advanced sclerosing
lesions [2]. More than one type of renal disease can
be present simultaneously, and the class of disease can
change over time [3]. The histologic disease can also be
classified according to activity and chronicity indices [4].
Activity and chronicity indices quantitate damage that is
thought to be recent and potentially reversible or long-
standing and irreversible. The prognosis and treatment
of lupus nephritis are different according to the ISN/RPS
class of disease present, activity, and chronicity [5–8].
Identification of ISN/RPS class and activity and chronic-
ity indices requires renal biopsy.
A diagnostic test based on urine proteins that could
identify the ISN/RPS class of lupus nephritis present and
indices of activity and chronicity would allow continuous
monitoring of these parameters without the morbidity,
cost, and inconvenience of renal biopsy. A number of
proteins or protein modifications have been proposed as
potential markers in lupus nephritis [9–12]. None have
been shown to be useful to differentiate disease class,
chronicity or activity. We have used two-dimensional gel
electrophoresis and artificial neural networks to identify
urinary protein spots that correlate with these clinical
measurements.
METHODS
Urine was collected from 20 consecutive patients
prior to undergoing renal biopsy for evaluation of lupus
2588
Oates et al: Urinary protein markers in lupus nephritis 2589
nephritis at the Medical University of South Carolina
according to a protocol approved by the Institutional
Review Board. Generally, patients were newly diag-
nosed with proteinuria and were not on more than
10 mg of prednisone. Ten of the patients were tak-
ing disease-modifying agents at the time the urine sam-
ple was collected (hydroxychloroquine-7, azathioprine-1,
mycophenolate mofetil-2). An experienced renal pathol-
ogist determined ISN/RPS classification of the disease
and indices of activity and chronicity prior to analy-
sis of the urine proteins. Cellular elements and debris
were removed by centrifugation. Samples were frozen
at −80◦C until they were prepared for two-dimensional
gel electrophoresis. After thawing, an equal volume of
acetone was added to 10 mL of urine and incubated for
10 minutes. The 9000 × g precipitate was resuspended
in 100 lL of a buffer containing 7 mol/L urea, 2 mol/L
thiourea, 2% CHAPS and 1% ASB-14. One gel was run
for each patient. A complete description of the urine sam-
ple preparation and two-dimensional gel electrophoresis
protocol can be found in the MI2DG protocol database
at http://bioinformatics.musc.edu/mi2dg (protocol name
Precipitated Urine 1). This publicly accessible data base
is designed to describe all of the important variables in
two-dimensional gel electrophoresis in sufficient detail to
limit variability between laboratories.
Urine protein concentration was adjusted to 200 lg in
185 lL with a buffer containing 7 mol/L urea, 2 mol/L
thiourea, 2% CHAPS, 1% ASB-14, 0.2% 3 to 10 am-
pholytes, and 50 mmol/L dithiothreitol (DTT). Two-
dimensional electrophoresis was performed as previously
described over a pH range of 4 to 7 and on 8% to 16%
gradient sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) gels [13]. Gels were stained
overnight with Sypro Ruby (Molecular Probes, Eugene,
OR, USA) and imaged on an FX Pro Plus fluorescent
imager (Bio-Rad, Hercules, CA, USA). Gel images were
aligned using PDQuest software. Protein matches and
intensities were converted to a Web-based open-source
public infrastructure called annotated gel markup lan-
guage (AGML) as previously described [14, 15]. The
AGML formatted structure was processed by code writ-
ten in MATLAB (MathWorks Inc), and spot intensities
were ranked by intensity and expressed as quantiles [16].
An artificial neural network models was trained using the
ranked protein intensities for 213 spots and three demo-
graphic parameters (gender, race, and age) by MATLAB
code written along the guidelines previously proposed
[17]. The artificial neural network fits a universal func-
tion to the input data using an iterative approach where
each change in the function is evaluated to determine
its effect on the accuracy of the outputs. The predictive
value of each spot was evaluated by sensitivity analy-
sis. Each seven artificial neural network classifiers were

















Fig. 1. Two-dimensional gel separation of proteins from a patient with
class V lupus nephritis. Proteins were stained with Sypro Ruby. Num-
bers correspond to proteins that were important in identifying the In-
ternational Society of Nephrology/Renal Pathology Society (ISN/RPS)
class, activity, and chronicity as listed in Table 2.
(ROC) curves were determined to assess the accuracy of
the results for ISN/RPS class and indices of activity and
chronicity. The data from all 20 patients was then used
to predict the classification of the training set. Sensitivity
and specificity values were calculated for each diagnosis.
RESULTS
Urine was collected from twenty consecutive patients
with SLE at the time of renal biopsy. There were five
Caucasians, 15 African-Americans, two males and 18 fe-
males. Mean age was 27 ± 8 years. ISN/RPS class of lupus
nephritis and indices of activity and chronicity were deter-
mined by a renal pathologist. Nine patients had histologic
characteristics of more than one class of lupus nephritis
and were assigned to more than one ISN/RPS class.
A representative example of a two-dimensional gel of
urine proteins from a patient with class V lupus nephri-
tis is shown in Figure 1. We aligned 213 protein spots
across the gels. Analysis by artificial neural networks
was done on protein abundance normalized by quantile.
Output values were the binary value for each ISN/RPS
class II, III, IV, and V and an ordinal value for activity
and chronicity. ROC curves were derived for ISN/RPS
classes. The area under the curve (AUC) for the ROC
curve was greater than 0.85 for all classes. The r value for
activity index was a relatively poor 0.77, but the r value
for the chronicity index was much better at 0.87 (Table 1).
ROC AUC and correlation coefficient are not reported
for class II since there were only two positive diagnoses.
The original data set was analyzed by the trained artifi-
cial neural networks to determine its ability to predict the
disease. For each gel, a prediction of presence or absence
of each class of lupus nephritis was given. Sensitivity was
86% or greater for all classes. The sensitivity was lowest in
class III disease, in which six of the seven cases were cor-
rectly identified. The specificity was 92% or greater for all
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Table 1. Statistics of sample classification by artificial neural networks
II III IV V Activity Chronicity
Number 2 7 8 12
Receiver operating characteristics, NR 0.93 0.95 0.85
area under the curve
Correlation coefficient, r NR 0.89 0.86 0.59 0.77 0.87
Sensitivity 100 86 100 92
Specificity 100 100 92 50
NR is not reported.
classes except V, where only four of the eight patients who
were negative for class V were correctly identified. Inter-
estingly, all the false positive identifications of class V had
class III or IV lupus present and were correctly identified
as such. Clinically, a patient with both proliferative (class
III or IV) and membranous (class V) would be treated
for the more aggressive proliferative lesion, so the false
positive identification of class V would not have affected
the treatment of the patient.
In addition to being useful for identifying the ISN/RPS
class of lupus nephritis, urine markers could be used to
predict the duration and amount of renal injury from the
disease. We have trained the artificial neural networks
to correlate with the histologic score for chronicity and
activity. A high degree of correlation was obtained for
chronicity (r = 0.87) (Fig. 2), and a lesser degree of cor-
relation was obtained for the activity index (r = 0.77).
It is worth recalling that these values are cross-validated
and that the artifical neural network classifiers selected
correspond to the median performer of a set of artificial
neural network models that rely on different resampled
subsets of the available data [1]. Therefore, the results
obtained are representative to the same extent that the
data set itself is sufficiently representative.
Classification of patients was based on patterns of pro-
tein abundance. In order to derive a clinically useful test
to predict class, activity, and chronicity of lupus nephritis,
the identity of the proteins that provide the most sen-
sitivity in the trained network needs to be determined.
Both the amount of sensitivity for an individual protein
in a given gel and the overall amount of sensitivity for the
analysis was determined. Analysis of sensitivity for each
of the outcomes was performed. Interestingly, most of the
sensitivity was derived by a limited set of spots. Table 2
lists in order the ten spot numbers or demographic fac-
tors that provided the most sensitivity. Spot numbers 5,
77, and 44 were near the top for amount of sensitivity pro-
vided for most of the analyses. None of the spots alone
could differentiate between classes. Race, gender, or age
were important in the analysis for several diagnoses. Total
amount of sensitivity provided by the top ten variables for
each diagnosis is shown at the bottom of the table. Using
matrix-assisted laser desorption-ionization tandem mass
spectrometry (MALDI-TOF-TOF) and informatic tools












Fig. 2. Predicted vs. observed values from a trained artificial neural
network for chronicity index. A correlation with a Pearson’s correlation
coefficient of 0.87 was obtained. Symbols are: (◦), training data; (•),
internal validation set.
highest sensitivity: spot 5, a-1 acid glycoprotein; spot 44,
a1 microglobulin; spot 52, zinc a-2 glycoprotein; spot 53,
zinc a-2 glycoprotein; spot 75, IgG j light chain; and spot
77, a1 microglobulin.
DISCUSSION
Global protein quantitation strategies provide an op-
portunity to identify biomarkers that can identify diseases
in a manner not possible with the candidate approach
based on more limited numbers of proteins [18]. Quan-
tification of urine proteins by two-dimensional gel elec-
trophoresis was first done in the 1970s [19]. In spite of this,
relatively little progress has been made to identify uri-
nary biomarkers. Proteomic techniques have been used to
look for urinary protein markers for stroke [20], bladder
carcinoma [21], radiocontrast administration [22], and
skeletal muscle toxicity [23]. Recently, surface-enhanced
laser desorption and ionization (SELDI) has been used
to identify urinary markers of acute renal allograft re-
jection [24–26]. These studies have provided interesting
information about urine protein profiles but have not yet
described a set of proteins that can be easily adapted to
create a clinically useful test.
The studies described here have demonstrated an ap-
proach to urinary biomarker identification that success-
fully identified protein spots that can serve as surrogates
for a renal biopsy to identify class and chronicity index
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Table 2. Ranked sensitivities for diagnosis of lupus class, activity, and chronicity
International Society of
Nephrology/Renal Pathology Society Class
Histologic parameter II III IV V Activity Chronicity
Spot numbers or clinical variables 5 5 5 5 77 5
ranked by sensitivity
77 77 77 77 44 44
44 52 44 44 5 77
22 124 Race 75 Age 141
53 69 28 80 53 Age
141 67 Gender 27 28 75
28 165 69 53 98 98
69 133 165 6 79 28
125 27 75 81 75 69
60 53 60 23 Race 53
Total sensitivity % 62 41 49 66 57 50
of disease in this cohort. The set of patients used in the
analysis included patients who had more than one coex-
isting class of lupus nephritis. This set mimics patients that
would be seen in the clinic for whom the diagnostic assay
would be most useful. Evaluation of chronicity by urine
test would also be very useful although as demonstrated
in Figure 2, the correlation between predicted and ob-
served is better in this set for nonzero values of chronic-
ity. We have identified six of the protein spots as four
unique proteins. These proteins are glycosylated serum
proteins. Zinc a-2 glycoprotein and a1 microglobulin are
both present in at least two charge forms among the pro-
teins we have identified. These data suggest that differ-
ences in alterations in glomerular permeability to charged
proteins may be partially responsible for the ability of
the urine proteins to serve as biomarkers. The identity
of the other proteins may reflect altered glomerular per-
meability to specific proteins, altered renal metabolism,
or proteins that originate within the glomerulus, tubule,
or interstitium or from inflammatory cells. The machine
learning model was not able to predict activity index and
has a false positive and false negative rate for the other
diagnoses that would be unacceptable for a clinical assay.
A larger numbers of patients will need to be studied in or-
der to create models that can more reliably predict classes,
chronicity, and activity. The current model will require ex-
ternal validation in a new set of patients. This validation
should be done after antibodies are raised to the proteins
that provide the most sensitivity and are validated. A clin-
ically useful multiplexed enzyme-linked immunosorbent
assay (ELISA)-type assay could be developed based on
antibodies generated against these proteins and would
be more sensitive, reproducible, simple and rapid than
two-dimensional gel electrophoresis.
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